Paliperidone for schizophrenia

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2008, Pages

  Nussbaum, Abraham ^a   Stroup, T S ^b  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; OLANZAPINE; PALIPERIDONE; PLACEBO;

AGGRESSION; AGITATION; AKATHISIA; ANXIETY; ASTHENIA; BEHAVIOR; BLOOD PRESSURE; BODY MASS; CLINICAL TRIAL; COGNITION; CONFIDENCE INTERVAL; CONSTIPATION; CREATINE KINASE BLOOD LEVEL; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ECONOMIC ASPECT; ELECTROCARDIOGRAM; GLUCOSE BLOOD LEVEL; HEADACHE; HOSPITALIZATION; HUMAN; HYPERKINESIA; HYPERTENSION; HYPOTENSION; INCIDENCE; INSOMNIA; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MENTAL HEALTH; MORTALITY; MOTOR DYSFUNCTION; MUSCLE HYPERTONIA; MUSCULOSKELETAL PAIN; NAUSEA; PAIN; PATIENT COMPLIANCE; PATIENT SATISFACTION; PROLACTIN BLOOD LEVEL; PSYCHOSIS; QT INTERVAL; QUALITY OF LIFE; RASH; RECURRENT DISEASE; REVIEW; RISK; SALIVA; SALIVATION; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL INTERACTION; SOMNOLENCE; TACHYCARDIA; TOOTH PAIN; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN;

EID: 44949159898     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006369.pub2     Document Type: Review

References (72)

1. Davidson 2007 {published and unpublished data} Davidson M, Emsley R, Kramer M, Ford L. Efficacy, safety and effect on functioning of paliperidone extended-release tablets in schizophrenia: an international 6-week placebo-controlled study. 13th Biennial Winter Workshop on Schizophrenia; Davos, Switzerland. 2006 February 4-10.
2. *Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P, Eerdekens M. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophrenia Research 2007;93(1-3):117-30. [MEDLINE: 17466492].
3. Davidson M, Emsley R, Kramer M, Gassmann-Mayer C, Lim P, Pan J, Eerdekens M. Efficacy, safety and effect on functioning of oral paliperidone extended-release tablets in the acute treatment of schizophrenia: an international 6-week placebo-controlled study. Schizophrenia Research 2006;81(Suppl 1):43.
4. Janssen-Cilag Ltd. Data on File PCDoF2. Communication from Janssen-Cilag Ltd.
5. Kane 2007 {published and unpublished data} Janssen-Cilag Ltd. Data on File PCDoF2. Communication from Janssen-Cilag Ltd.
6. *Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo -controlled trial. Schizophrenia Research 2007;90(3):147-61. [MEDLINE: 17092691].
7. Kane J, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M. Patients with acute schizophrenia: treatment with three fixed dosages of oral paliperidone extended-release tablets in an international 6-week placebo-controlled study. 159th Annual Meeting of the American Psychiatric Association; Toronto, Canada. 2006 May 20-25.
8. Kane J, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M. Treatment of schizophenia using oral paliperidone extended-release tablets: a 6-week placebo-controlled study. 13th Biennial Winter Workshop on Schizophrenia; Davos, Switzerland. 2006 February 4-10.
9. Kramer 2007 {published data only} Kramer M, Kushner S, Vijapurkar U, Lim P, Eerdekens M. Delaying symptom recurrence in patients with schizophrenia treated with paliperidone extended-release tablets. Journal of the European College of Neuropsychopharmacology 2006;16(Suppl 4):s386.
10. *Kramer M, Simpson G, Maciulis V, Kushner S, Vijapurkar U, Lim P, Eerdekens M. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology 2007;27(1):6-14. [MEDLINE: 17224706].
11. Marder 2007 {published and unpublished data} Janssen-Cilag Ltd. Data on File PCDoF2. Communication from Janssen-Cilag Ltd.
12. Marder S, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M. A 6-week, US-based placebo-controlled study on the efficacy and tolerability of two fixed dosages of oral paliperidone extended-release tablets in the treatment of acute schizophrenia. 159th Annual Meeting of the American Psychiatric Association; Toronto, Canada. 2006 May 20-25.
13. Marder S, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of schizophrenia: a 6-week controlled study. Schizophrenia Research 2006;81(Suppl 1):56.
14. *Marder S, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, Lowy A. Efficacy and safety of paliperidone extended-release tablets: results of a six-week, randomized, placebo-controlled study. Biological Psychiatry 2007;62(12):1363-70. [MEDLINE: 17601495].
15. Tzimos 2006 {published data only} *Tzimos A, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M. A 6-week placebo-controlled study of the safety and tolerability of flexible doses of oral paliperidone extended-release tablets in the treatment of schizophrenia in elderly patients. 25th Collegium Internationale Neuro-psychopharmacologicum; Chicago, Illinois. 9-13 July 2006.
16. Tzimos A, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M. A 6-week placebo-controlled study on the safety and tolerability of flexible doses of oral paliperidone extended-release tablets in the treatment of schizophrenia in elderly patients. 159th Annual Meeting of the American Psychiatric Association; Toronto, Canada. 2006 May 20-25.
17. Tzimos A, Kramer M, McLemore J, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M. A 6-week placebo-controlled study of the safety and tolerability of flexible doses of oral paliperidone extended-release tablets in the treatment of schizophrenia in elderly patients. Schizophrenia Bulletin. 2007; Vol. 33, issue Suppl 2:s464.
18. Arakawa 2007 Arakawa R, Ito H, Takano A, Takahashi H, Morimoto T, Sassa T, Ohta K, Kato M, Okubo Y, Suhara T. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D(2) receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl) 2007;epub ahead of print:epub ahead of print. [MEDLINE: 18058087].
19. Borison 1994 Borison R, Diamond B, Pathiraja A, Meibach R. Pharmacokinetics of risperidone in chronic schizophrenic patients. Psychopharmacology Bulletin 1994;30(2):193-7. [MEDLINE: 7530379].
20. Cleton 2006 Cleton A, Talluri K, Leempoels A, Thyssen A, Janssens L, Eerdekens M, Boom S. No pharmacokinetic interaction between trimethoprim and paliperidone ER in healthy subjects. Clinical pharmacology and therapeutics 2006;79(2):22.
21. Cleton 2007a Cleton A, Rossenu S, Talluri K, Francetic I, Remmerie B, Janssens L, Eerdekens M, Boom S. Evaluation of the pharmacokinetics of an extended-release formulation of paliperidone with an immediate-release formulation of risperidone. Clinical pharmacology and therapeutics 2007;81(Supplement 1):S62.
22. Cleton 2007b Cleton A, Rossenu S, Boom S, Remmerie B, Alnabawy A, Talluri K, Eerdekens M. Evaluation of the pharmacokinetics of paliperidone extended-release tablets in healthy elderly subjects. Clinical pharmacology and therapeutics 2007;81(Supplement 1):S62.
23. Karlsson 2006 Karlsson P, Dencker E, Nyberg S, Cselenyi Z, Mannaert E, Boom S, Talluri K, Rossenu S, Eriksson B, Eerdekens M, Farde L. Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects. Schizophrenia Research 2006;81(Supplement 1):85-6.
24. Armenteros 2001 *Armenteros J. Risperidone treatment of adolescents with schizophrenia. CRISP database issue 2001.
25. Altman 1996 Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
26. Anonymous 2007 Anonymous. Molecule of the month. Paliperidone. Drug News Perspective 2007;20(5):333. [MEDLINE: 17878961].
27. Aravagiri 1998a Aravagiri M, Yuwiler A, Marder S. Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxyrisperidone in the brain and other tissues of rat. Psychopharmacology 1998;139(4):356-63. [MEDLINE: 9809856].
28. Aravagiri 1998b Aravagiri M, Marder S, Wirshing D, Wirshing W. Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection. Pharmacopsychiatry 1998;31(3):102-9. [MEDLINE: 9657237].
29. Aravagiri 2000 Aravagiri M, Marder S. Simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma by liquid chromatography/ electrospray tandem mass spectrometry. Journal of Mass Spectrometry 2000;35(6):718-24. [MEDLINE: 10862124].
30. Aravagiri 2002 Aravagiri M, Marder S. Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. Psychopharmacology 2002;159(4):424-31. [MEDLINE: 11823895 11823895].
31. Aravagiri 2003 Aravagiri M, Marder S, Nuechterlein K, Gitlin M. Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone. Therapeutic Drug Monitoring 2003;25(6):657-64. [MEDLINE: 14639051].
32. Ascher-Svanum 2006 Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. Journal of Clinical Psychiatry 2006;67(3):453-60.
33. Awouters 2007 Awouters FH, Lewi PJ. Forty years of antipsychotic Drug research from haloperidol to paliperidone with Dr. Paul Janssen. Arzneimittelforschung 2007;57(10):625-32. [MEDLINE: 18074755].
34. Barnes 1989 Barnes TR. A rating scale for drug-induced akathisia. British Journal of Psychiatry 1989;154:672-6. [MEDLINE: 2574607].
35. Byerly 2007 Byerly M, Suppes T, Tran QV, Baker RA. Clinical Implications of Antipsychotic-Induced Hyperprolactinemia in Patients With Schizophrenia Spectrum or Bipolar Spectrum Disorders: Recent Developments and Current Perspectives. Journal of Clinical Psychopharmacology 2007;27(6):639-61. [MEDLINE: 18004132].
36. Citrome 2007 Citrome L. Paliperidone: quo vadis?. International Journal of Clinical Practice 2007;61(4):653-62. [MEDLINE: 17343660].
37. Deeks 2005 Deeks JJ, Higgins JPT, Altman DG. Analysing and presenting results. In: HigginsJPT, GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]; Section 8: The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd, 2005.
38. Dirks 2006 Dirks B, Canuso C, Eerdekens M, Turkoz I, Alberio R, Gharabawi G. Efficacy of paliperidone extended-release tablets in patients with schizophrenia and predominant negative symptoms. Collegium Internationale Neuro-Psychopharmacology 25th Biennial Congress; Chicago, Illinois. 2006 July 9-13.
39. Duggal 2007 Duggal HS. Possible neuroleptic malignant syndrome associated with paliperidone. Journal of Neuropsychiatry Clinical Neuroscience 2007;19(4):477-8. [MEDLINE: 18070861].
40. Freedman 2003 Freedman R. Schizophrenia. New England Journal of Medicine 2003;349(18):1738-49.
41. Gagnon 2006 Gagnon D, Adriaenssen I, Nasrallah H, Morosini P. Reliability, validity and sensitivity to change of the personal and social performance scale in patients with stable schizophrenia. International Journal of Neuropsychopharmacology 2006;9(Suppl 1):288.
42. Gilbody 2000 Gilbody SM, Bagnall AM, Duggan L, Tuunainen A. Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews 2000, Issue 3.Art. No.: CD002306. DOI:10.1002/14651858.CD002306.
43. Gulliford 1999 Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149(9):876-83.
44. Guy 1976 Guy W. Early clinical drug evaluation (ECDEU) assessment manual for psychopharmacology. Washington DC: National Institute of Mental Health, 1976.
45. Heinrichs 1984 Heinrichs DW, Hanlon ET, Carpenter WT. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 1984;10(3):388-96. [MEDLINE: 6474101].
46. Higgins 2005 Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd, 2005.
47. Hogarty 1974 Hogarty GE, Goldberg SC, Schooler NR, Ulrich RF. Drug and sociotherapy in the aftercare of schizophrenic patients: two-year relapse rates. Archives of General Psychiatry 1974;31:603-8.
48. Hosalli 2003 Hosalli P, Davis JM. Depot risperidone for schizophrenia. Cochrane Database of Systematic Reviews 2003, Issue 4.Art. No.: CD004161. DOI:10.1002/14651858.CD004161.
49. Hunter 2003 Hunter RH, Joy CB, Kennedy E, Gilbody SM, Song F. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews 2003, Issue 2.Art. No.: CD000440. DOI:10.1002/14651858.CD000440.[MEDLINE: Art. No.: CD000440].
50. Janicak 2006 Janicak PG, Davis JM, Preskorn SH, Ayd FJ, Marder SR, Pavuluri MN. Principles and Practice of Psychopharmacology. 4th Edition. Philadelphia: Lippincott Williams and Wilkins, 2006.
51. Janssen 2003 Janssen Pharmaceutica Products LP. Risperdal Consta (risperidone) long-acting injection prescribing information. Janssen Pharmaceutica Products, L.P Oct 2003.
52. Janssen 2006 Janssen Pharmaceutica Products LP. Invega (paliperidone) extended-release tablets prescribing information. Janssen Pharmaceutica Products, L.P Dec 2006.
53. Janssen-Cilag 1996 Janssen-Cilag Ltd. Risperidal (risperidone) summary of product characteristics. UK: Janssen-Cilag Ltd, 1996.
54. Jayaram 2006 Jayaram MB, Hosalli P, Stroup S. Risperidone versus olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 2.Art. No.: CD005237. DOI:10.1002/14651858.CD005237.pub2.
55. Kapur 1995 Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Science 1995;57(10): 103-7. [MEDLINE: 7543969].
56. Kay 1986 Kay S, Opler L, Fizbein A. The positive and negative syndrome scale (PANSS) manual. North Tohawanda, NY: Multi-Health System, 1986.
57. Knegtering 2005 Knegtering R, Baselmans P, Castelein S, Bosker F, Bruggeman R, van den Bosch R. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. American Journal of Psychiatry 2005;162(5):1010-2. [MEDLINE: 15863810].
58. Leon 2007 Leon J, Susce MT, Pan RM, Wedlund PJ, Orrego ML, Diaz JF. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 2007;40(3):93-102. [MEDLINE: 17541883].
59. Lieberman 2005 Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353(12):1209- 23. [MEDLINE: 16172203].
60. Lieberman 2006 Lieberman JA, Stroup TS, Perkins DO. The American Psychiatric Publishing Textbook of Schizophrenia. Washington, DC: American Psychiatric Publishing, 2006.
61. Mackay 1998 Mackay FJ, Wilton LV, Pearce GL, Freemantle SN, Mann RD. The safety of risperidone: a post-marketing study on 7684 patients. Human Psychopharmacology 1998;13:413-8.
62. Mannens 1993 Mannens G, Huang M-L, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J. Absorption, metabolism, and excretion of risperidone in humans. Drug Metabolism and Disposition 1993;21(6):1134-41.
63. Marder 1997 Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials. Journal of Clinical Psychiatry 1997;58(12):538-46. [MEDLINE: 9448657].
64. Marshall 2000 Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:259-62.
65. McEvoy 2006 McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. Journal of Clinical Psychiatry 2006;67(Suppl 5):15-8. [MEDLINE: 16822092].
66. Melkersson 2006 Melkersson K. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Human Psychopharmacology 2006;21(8):529-32. [MEDLINE: 17094165].
67. Moher 2001 Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-91.
68. Patrick 2006 Patrick D, Adriaenssen I, Morosini P, Rothman M. Reliability, validity and sensitivity to change of the personal and social performance scale in patients with acute schizophrenia. International Journal of Neuropsychopharmacology 2006;9(Suppl 1):S287-S288.
69. Simpson 2006 Simpson G. Paliperidone: long-acting antipsychotic can be taken once daily. Current Psychiatry 2006;5(11):118-120.
70. Simpson 2007 Simpson G. Paliperidone Extended Release. CNS Drugs 2007;21(5):426-7.
71. Spina 2007 Spina E, Cavallaro R. The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia. Expert Opinion Drug Safety 2007;6(6):651-62. [MEDLINE: 17967154].
72. Vermeir 2005 Vermeir M, Boom S, Naessens I, Talluri K, Eerdekens M. Absorption, metabolism and excretion of a single oral dose of 14C-paliperidone 1 mg in healthy subjects. European Neuropsychopharmacology 2005;15(Suppl 3):S648-9.